Skip to main content

Juvenile Xanthogranuloma clinical trials at UC Cancer

1 research study open to eligible people

Showing trials for
  • Genetic Testing to Determine Therapy For Pediatric Relapsed or Refractory Advanced Solid Tumors

    open to eligible people ages 12 months to 21 years

    This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.

    at UC Davis UCLA UCSF

Our lead scientists for Juvenile Xanthogranuloma medical studies include .

Last updated: